Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) announce their experimental Zaltrap drug...

|About: Sanofi (SNY)|By:, SA News Editor

Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) announce their experimental Zaltrap drug didn't meet targets in a late-stage Phase III trial. Despite the miss, the firms say the FDA granted a priority review to examine the proposed treatment for colon cancer.